KMB
34
6
EFX
40
4
ORCL
58
4
TRV
48
2
UNH
55
5
SJM
19
5
FTI
66
2
BF.B
31
2
MLM
58
-2
TROW
54
6
EXPD
40
3
LRCX
48
6
AON
49
2
NI
63
3
BXP
49
2
JCI
45
4
AKAM
54
3
AFL
41
4
CSX
57
4
AEE
55
5
KMB
34
6
EFX
40
4
ORCL
58
4
TRV
48
2
UNH
55
5
SJM
19
5
FTI
66
2
BF.B
31
2
MLM
58
-2
TROW
54
6
EXPD
40
3
LRCX
48
6
AON
49
2
NI
63
3
BXP
49
2
JCI
45
4
AKAM
54
3
AFL
41
4
CSX
57
4
AEE
55
5
Financhill
Back

SpringWorks Therapeutics 10K Form

Sell
37

SWTX
SpringWorks Therapeutics

Last Price:
33.01
Seasonality Move:
44.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SWTX News And Ratings

See the #1 stock for the next 7 days that we like better than SWTX

SWTX Financial Statistics

Sales & Book Value

Annual Sales: $5.45M
Cash Flow: $-54.02M
Price / Cash Flow: 0
Annual Sales: $7.50
Price / Book: 4.21

Profitability

EPS (TTM): -4.44000
Net Income (TTM): $-301.06M
Gross Margin: $5.03M
Return on Equity: -57.97%
Return on Assets: -50.43%

SpringWorks Therapeutics Earnings Forecast

Key SpringWorks Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 3 years for SWTX is 92.25%.
  • The Selling, General & Administrative Expenses for SWTX have been equal to 3,626.79% of Gross Profit Margin.
  • The Research & Development expenses have been 2,762.75% of Revenue.
  • The Net Earning history of SWTX is -5,968.50% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

SpringWorks Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SWTX
CUSIP: 85205L
Website: springworkstx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.91
Quick Ratio: 7.49

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SWTX Technical Analysis vs Fundamental Analysis

Sell
37
SpringWorks Therapeutics (SWTX) is a Sell

Is SpringWorks Therapeutics a Buy or a Sell?